Kyverna Therapeutics added to Analyst Focus List at JPMorgan

JPMorgan analyst Brian Cheng added Kyverna Therapeutics to the firm’s Analyst Focus List as a “growth strategy” while keeping an Overweight rating on the shares with a $39 price target. Following the Autoimmune CAR-T Innovator Summit, the analyst says the company’s level of engagement within the physician community and enthusiasm from physicians were highly evident. The firm believes Kyverna has a “leading active cell therapy with curative potential.” The recent share weakness driven by concerns in the blincyto named cases is short-sighted, which creates an attractive entry point, the analyst tells investors in a research note.